The recent strategic alliance between Millennium and Bristol Myers Squibb Co. is a good example of the Cambridge firm's creative partnership prowess, Singer said. These two companies signed a $32 million deal last month to develop clinical markers that will be used to make diagnostic tests and target drugs to patients according to their individual genetic sensitivities and responses, an emerging practice called pharmacogenomics. The five-year alliance not only outlines the responsibilities of both parties, but creates a set of protocols for the selection of a third company to commercialize diagnostic products coming from the research and development.